Clinical Trial Update: Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the combination of immunotherapy with ADI-PEG 20 for advanced uveal melanoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Uveal Melanoma

Drugs mentioned

• ADI-PEG 20 (pegylated arginine deiminase)
• Immunotherapy (immunotherapy)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Uveal Melanoma | Phase 1 | Status: COMPLETED